Much Work Remains to Determine Optimal Immunotherapy Combinations

The field of cancer immunotherapy has greatly advanced during the last 7 years. Agents approved for the treatment of advanced melanoma by the U.S. Food and Drug Administration include the anti–CTLA-4 antibody ipilimumab (2011), the anti–PD-1 antibodies nivolumab (2014) and pembrolizumab (2014), ipilimumab combined with nivolumab (2015), and the oncolytic virus vaccine talimogene laherparepvec (T-VEC; 2015). In addition, the combination of the kinase inhibitors … (leggi tutto)